Canada markets closed
  • S&P/TSX

    20,156.36
    +156.77 (+0.78%)
     
  • S&P 500

    4,224.79
    +58.34 (+1.40%)
     
  • DOW

    33,876.97
    +586.89 (+1.76%)
     
  • CAD/USD

    0.8081
    -0.0011 (-0.13%)
     
  • CRUDE OIL

    73.64
    -0.02 (-0.03%)
     
  • BTC-CAD

    40,401.94
    -3,418.53 (-7.80%)
     
  • CMC Crypto 200

    786.71
    -63.63 (-7.48%)
     
  • GOLD FUTURES

    1,785.00
    +2.10 (+0.12%)
     
  • RUSSELL 2000

    2,286.09
    +48.35 (+2.16%)
     
  • 10-Yr Bond

    1.4840
    +0.0340 (+2.34%)
     
  • NASDAQ futures

    14,140.75
    +10.75 (+0.08%)
     
  • VOLATILITY

    17.89
    -2.81 (-13.57%)
     
  • FTSE

    7,062.29
    +44.82 (+0.64%)
     
  • NIKKEI 225

    28,785.90
    +774.97 (+2.77%)
     
  • CAD/EUR

    0.6783
    -0.0002 (-0.03%)
     

AlivaMab Discovery Services Expands Drug Discovery Platform with the Launch of New Antibody Engineering Department

·2 min read

Jonah Rainey, Ph.D., joins ADS to bring new breadth and depth of capabilities and expertise in discovering therapeutic antibody modalities

AlivaMab Discovery Services, LLC ("ADS"), a leader in the discovery of superior antibody therapeutics, today announced the establishment of its new Antibody Engineering Department, led by Jonah Rainey, Ph.D. Jonah joins ADS as Vice President of Antibody Engineering and brings 15 years' experience in antibody engineering, discovery, and development from Macrogenics Inc., MedImmune, LLC/AstraZeneca PLC, Gritstone bio, Inc., and, most recently, Immetas Therapeutics, Inc. Jonah's breadth of experience in antibody engineering includes bispecific antibodies, several of which have entered clinical trials, antibody drug conjugates, Fc modification, in vitro display for antibody discovery and optimization, and structural modeling.

"A growing number of leading pharmas and biotechs recognize that the already-existing platform process at ADS has created exceptional value for their antibody drug discovery efforts. I am excited to lead the effort to build new capabilities at ADS to expand the scope and value that we bring to our clients' drug discovery and development projects. The contribution of the new Antibody Engineering Department will further ensure that ADS delivers the best antibody drug candidates," said Jonah Rainey, Vice President of Antibody Engineering, of AlivaMab Discovery Services.

"Today we expand significantly the ADS discovery platform by adding a new pillar of antibody engineering to our existing pillars of Ablexis' AlivaMab® Mouse, the leading transgenic animal technology for antibody drug discovery, a suite of AMMPD immunization technologies to address even the most challenging targets, broad sampling of the immune repertoire through function-first high-throughput deep screening, and developability assessment," said Justin Mika, Chief Executive Officer at AlivaMab Discovery Services. "Jonah‘s talents and expertise strengthen and compliment the combined decades of experience in discovery and development of the ADS team. Through this combination of team, technology, and partnership, we support our clients in bringing better medicines to patients faster."

About AlivaMab Discovery Services

AlivaMab Discovery Services is a privately held biotechnology company with an integrated antibody therapeutic discovery platform that combines innovative technologies and deep expertise to deliver superior antibody therapeutics in rapid timelines. Through their careers, the team has executed over 200 discovery projects yielding several dozen antibody drug candidates in clinical trials. ADS delivers diverse panels of antibody therapeutic candidates with extensive molecular and epitope diversities, functional and kinetic characterization, and superior developability profiles. With a business model that focuses exclusively on partners and not developing an internal product pipeline, ADS is trusted by organizations ranging from global pharmaceutical companies to virtual biotechnology organizations. For more information, please visit www.alivamab.com or contact us at info@alivamab.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005153/en/

Contacts

BD Contact:
info@alivamab.com

Media Contact:
Stacey Borders
sborders@alivamab.com
(858) 252-3420 x105

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting